Trial reportThe British journal of dermatology2020
Long-term efficacy and safety of brodalumab in psoriasis through 120 weeks and after withdrawal and retreatment: subgroup analysis of a randomized phase III trial (AMAGINE-1).
Trial report in The British journal of dermatology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Comparison of the Effects and Safety of Planned Limited-Time Withdrawal Versus Continuous Maintenance of Interleukin Inhibitors in Patients with Psoriasis: A Systematic Review and Network Meta-Analysis.Dermatology and therapy · 2026Pooled it
- GWAS meta-analysis of psoriasis identifies new susceptibility alleles impacting disease mechanisms and therapeutic targets.Nature communications · 2025Pooled it
- Short-term risk and long-term incidence rate of infection and malignancy with IL-17 and IL-23 inhibitors in adult patients with psoriasis and psoriatic arthritis: a systematic review and meta-analysis.Frontiers in immunology · 2023Pooled it
- Time to Relapse After Discontinuing Systemic Treatment for Psoriasis: A Systematic Review.American journal of clinical dermatology · 2022Pooled it
- Brodalumab, an anti-interleukin-17 receptor A monoclonal antibody, in axial spondyloarthritis: 68-week results from a phase 3 study.Rheumatology (Oxford, England) · 2023Trial
- Long-term efficacy and safety of tildrakizumab in Japanese patients with moderate to severe plaque psoriasis: Results from a 5-year extension of a phase 3 study (reSURFACE 1).The Journal of dermatology · 2021Trial
- The Pathophysiological Significance of Dual Inhibition of IL-17A and IL-17F in Psoriatic Arthritis and Axial Spondyloarthritis.Mediterranean journal of rheumatology · 2026Review
- Interleukin-17 in disease pathogenesis and therapy: recent advances in targeted drug design and medicinal chemistry.Frontiers in pharmacology · 2026Review
- Baseline Th17/Tc17 and LAG-3 levels serve as candidate exploratory markers for early ixekizumab response in psoriasis.Frontiers in immunology · 2026Article
- Real-world Evidence of Brodalumab Safety for the Treatment of Psoriasis.Journal of psoriasis and psoriatic arthritis · 2025Review
- Brodalumab: Seven-Year US Pharmacovigilance Report.Dermatology and therapy · 2025Article
- IL-17 Class Inhibitors and Plaque Psoriasis: Not All Biologics Relapse Equally.The Journal of clinical and aesthetic dermatology · 2025Article
- Indirect Comparison Between Bimekizumab and Brodalumab for the Management of Moderate to Severe Psoriasis: A 36-Week Real-Life Study.Dermatology and therapy · 2025Article
- A real-world Pharmacovigilance study of brodalumab based on the FDA adverse event reporting system.Scientific reports · 2025Article
- Machine Learning-Driven Prediction Models for Brodalumab Therapeutic Effect and Response Speed in Plaque Psoriasis.Psoriasis (Auckland, N.Z.) · 2025Article
- Biologics and small molecules for psoriasis: current and future progress.Drugs in context · 2025Review
- Real-world experience with brodalumab in a Portuguese cohort of patients with moderate-to-severe psoriasis.Drugs in context · 2025Article
- Brodalumab: Six-Year US Pharmacovigilance Report.Dermatology and therapy · 2025Article
- Real-World Data on Brodalumab Treatment in Patients with Moderate-to-Severe Plaque Psoriasis: An Observational Study from the Czech Republic BIOREP Registry.Advances in therapy · 2024Observational
- The Impact of Psoriasis Treatments on the Risk of Skin Cancer: A Narrative Review.Advances in therapy · 2024Review
Corrections and comments
- Commented on by
Authors and funding
7 authors.
Funding
Abstract
backgroundBrodalumab is efficacious for the treatment of moderate-to-severe plaque psoriasis through 52 weeks.
objectivesTo evaluate the efficacy and safety of brodalumab through 120 weeks, including following withdrawal and retreatment.
methodsAt baseline, patients were randomized to brodalumab (n = 222) or placebo (n = 220). At week 12, patients achieving a static Physician's Global Assessment (sPGA) score of 0 or 1 (sPGA 0/1) with brodalumab were rerandomized to brodalumab (n = 83) or placebo (n = 84; later re-treated with brodalumab if sPGA ≥ 3 occurred), and patients receiving placebo switched to brodalumab (n = 208). Safety was assessed by exposure-adjusted rates of treatment-emergent adverse events.
resultsAmong those who achieved sPGA 0/1 at week 12 and were rerandomized to brodalumab, 96% and 80% using observed data, respectively, and 74% and 61% using nonresponder imputation, respectively, achieved 75% improvement in Psoriasis Area and Severity Index (PASI 75) and PASI 100 at week 120. Following withdrawal from brodalumab, return of disease occurred after a mean ± SD duration of 74·7 ± 50·5 days. Among those who switched from brodalumab to placebo at week 12, PASI 75 rates using observed data and nonresponder imputation were 55% and 51% at week 20, respectively and 94% and 75% at week 120, respectively; PASI 100 rates at week 120 were 75% and 60%, respectively. Efficacy was maintained through week 120 in those receiving brodalumab after placebo. No new safety signals were observed.
conclusionsThese findings indicate that brodalumab is efficacious and safe for continuous long-term treatment of psoriasis, and support the potential for response after discontinuation and retreatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.